PMID- 18307019
OWN - NLM
STAT- MEDLINE
DCOM- 20080724
LR  - 20211020
IS  - 1341-9625 (Print)
IS  - 1341-9625 (Linking)
VI  - 13
IP  - 1
DP  - 2008 Feb
TI  - Treatment outcomes and dose-volume histogram analysis of simultaneous integrated 
      boost method for malignant gliomas using intensity-modulated radiotherapy.
PG  - 48-53
LID - 10.1007/s10147-007-0722-6 [doi]
AB  - BACKGROUND: The aim of this article is to report the treatment outcomes, 
      toxicities, and dosimetric feasibility of our simultaneous-boost 
      intensity-modulated radiotherapy (SIB-IMRT) protocol. METHODS: Thirteen patients 
      with malignant gliomas treated between December 2000 and September 2004 were 
      enrolled in this study. Two planning target volumes (PTVs) were defined in the 
      present study. Our IMRT regimen delivered 70 Gy/28 fractions (fr)/daily; 2.5 Gy 
      to the gross tumor volume (GTV) with a 0.5-cm margin, defined as the PTV-G, and 
      56 Gy/28 fr/daily, with 2.0 Gy to the surrounding edema, defined as the planning 
      target volume annulus (PTV-a). Eleven of the 13 patients received one or two 
      courses of nimustine hydrochloride (ACNU) (100 mg/m(2)) and vincristine (1.2 
      mg/body) and interferon-beta (3 x 10(6) units) three times weekly during the 
      period of radiotherapy. Adjuvant chemotherapy, ACNU (100 mg/m(2)) and vincristine 
      (1.2 mg/body), was repeated every 6 weeks and interferon-beta was repeated every 
      2 weeks. The treatment outcomes, toxicity, and dosimetric feasibility were 
      assessed. RESULTS: All the patients experienced tumor recurrence. The median 
      progression-free survival times for patients with grade III tumors and 
      glioblastome were 7.5 and 8.0 months, respectively. The 1-year and 2-year overall 
      survival rates for all the patients were 77% and 31%, respectively. Four patients 
      experienced acute grade 1/2 toxicities during the treatment. No late toxicity 
      related to radiotherapy has been seen. Analyses with dose-volume histograms 
      confirmed excellent conformity of dose distributions in the two target volumes, 
      PTV-G and PTV-a, with the sparing of organs at risk. CONCLUSION: Our IMRT regimen 
      did not prevent tumor progression. However, the ability of IMRT to deliver highly 
      conformative doses to two contiguous targets, GTV and the surrounding edema, 
      justifies its application to malignant gliomas.
FAU - Nakamatsu, Kiyoshi
AU  - Nakamatsu K
AD  - Department of Radiation Oncology, Kinki University School of Medicine, Osaka, 
      Japan.
FAU - Suzuki, Minoru
AU  - Suzuki M
FAU - Nishimura, Yasumasa
AU  - Nishimura Y
FAU - Kanamori, Shuichi
AU  - Kanamori S
FAU - Koike, Ryuta
AU  - Koike R
FAU - Shibata, Toru
AU  - Shibata T
FAU - Shintani, Naoya
AU  - Shintani N
FAU - Okumura, Masahiko
AU  - Okumura M
FAU - Okajima, Kaoru
AU  - Okajima K
FAU - Akai, Fumiharu
AU  - Akai F
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20080229
PL  - Japan
TA  - Int J Clin Oncol
JT  - International journal of clinical oncology
JID - 9616295
SB  - IM
MH  - Adult
MH  - Aged
MH  - Brain Neoplasms/mortality/*radiotherapy
MH  - Chemotherapy, Adjuvant
MH  - Female
MH  - Glioma/mortality/*radiotherapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Radiotherapy Dosage
MH  - Radiotherapy Planning, Computer-Assisted
MH  - *Radiotherapy, Intensity-Modulated
MH  - Survival Rate
MH  - Treatment Outcome
EDAT- 2008/03/01 09:00
MHDA- 2008/07/25 09:00
CRDT- 2008/03/01 09:00
PHST- 2007/07/11 00:00 [received]
PHST- 2007/09/05 00:00 [accepted]
PHST- 2008/03/01 09:00 [pubmed]
PHST- 2008/07/25 09:00 [medline]
PHST- 2008/03/01 09:00 [entrez]
AID - 10.1007/s10147-007-0722-6 [doi]
PST - ppublish
SO  - Int J Clin Oncol. 2008 Feb;13(1):48-53. doi: 10.1007/s10147-007-0722-6. Epub 2008 
      Feb 29.